Table 1.
Study population, patients who developed or did not develop new-onset PsA during biologic treatment: general features.
| Study Population | PsA Development | Non PsA | P | |
|---|---|---|---|---|
| Number of patients | 118 | 10 (8.5%) | 108 (91.5%) | |
| Sex: | ||||
| Male | 76 (64.4%) | 3 (30.0%) | 73 (67.6%) | ns |
| Female | 42 (35.6%) | 7 (70.0%) | 35 (32.4%) | ns |
| Mean age (years) | 48.4 ± 14.2 | 44.5 ± 13.4 | 48.8 ± 14.2 | ns |
| Mean duration of Psoriasis (years) | 18.4 ± 12.4 | 14.2 ± 8.3 | 18.8 ± 12.6 | ns |
| Psoriasis activity | ||||
| PASI | 2.2 ± 6.2 | 1.8 ± 2.9 | 2.2 ± 6.5 | ns |
| BSA | 2.6 ± 5.6 | 4.6 ± 8.7 | 2.4 ± 5.2 | ns |
| Time of treatment (months) | 36.1 ± 26.4 | 26.1 ± 21.6 | 37.0 ± 26.7 | ns |
| Comorbidities: | ||||
| Absence of comorbidities | 59 (50.0%) | 6 (60.0%) | 53 (49.1%) | ns |
| Hypertension | 16 (13.6%) | 1 (10.0%) | 15 (13.9%) | ns |
| Diabetes mellitus | 12 (10.2%) | 1 (10.0%) | 11 (10.2%) | ns |
| Dyslipidemia | 24 (20.3%) | 1 (10.0%) | 23 (21.3%) | ns |
| Hidradenitis | 1 (0.8%) | 0 | 1 (0.9%) | ns |
| Obesity | 15 (12.7%) | 0 | 15 (13.9%) | ns |
| Hypothyroidism | 2 (1.7%) | 1 (10.0%) | 1 (0.9%) | ns |
| Hyperthyroidism | 0 | 0 | 0 | ns |
| Acute myocardial infarction | 1 (0.8%) | 0 | 1 (0.9%) | ns |
| Cardiopathy | 2 (1.7%) | 0 | 2 (1.9%) | ns |
| Chronic obstructive pulmonary disease | 2 (1.7%) | 0 | 2 (1.9%) | ns |
| Hepatitis B | 1 (0.8%) | 0 | 1 (0.9%) | ns |
| Hepatitis C | 1 (0.8%) | 0 | 1 (0.9%) | ns |
| Polycistic ovary syndrome | 1 (0.8%) | 0 | 1 (0.9%) | ns |
| Other (vitiligo, glaucoma, ulcerative colitis, hives) | 5 (4.2%) | 1 (10.0%) | 4 (3.7%) | ns |
| Previous treatments (conventional and small-molecules): | ||||
| Apremilast | 5 (4.2%) | 1 (10.0%) | 4 (3.7%) | ns |
| Methotrexate | 40 (33.9%) | 3 (30.0%) | 37 (34.3%) | ns |
| Cyclosporine | 47 (39.8%) | 2 (20.0%) | 45 (41.7%) | ns |
| Acitretin | 10 (8.5%) | 1 (10.0%) | 9 (8.3%) | ns |
| Topical corticosteroids | 49 (41.5%) | 6 (60.0%) | 43 (39.8%) | ns |
| Nb-UVB Phototherapy | 13 (11.0%) | 1 (10.0%) | 12 (11.1%) | ns |
| Dimethyl-fumarate | 1 (0.8%) | 0 | 1 (0.9%) | ns |
| Psoralen-UVA | 2 (1.7%) | 0 | 2 (1.9%) | ns |
| Previous biologic treatments: | ||||
| Biologic naïve | 84 (71.2%) | 5 (50%) | 79 (73.1%) | ns |
| Anti-TNF-α | 26 (22.0%) | 4 (40.0%) | 22 (20.4%) | ns |
| Anti IL-23 | 1 (0.8%) | 1 (10.0%) | 0 | ns |
| Anti IL-17 | 14 (11.9%) | 2 (20.0%) | 12 (11.1%) | ns |
| Anti IL-12/23 | 9 (7.6%) | 2 (20.0%) | 7 (6.5%) | ns |
| Current biologic treatment: | ||||
| Anti-TNFα | ||||
| Etanercept | 4 (3.4%) | 1 (10.0%) | 3 (2.8%) (75.0%) | ns |
| Adalimumab | 25 (21.2%) | 2 (20.0%) | 23 (21.3%) (92.0%) | ns |
| Certolizumab | 2 (1.7%) | 0 | 2 (1.9%) (100%) | ns |
| Anti-IL12/23 | ||||
| Ustekinumab | 27 (22.9%) | 2 (20.0%) | 25 (23.1%) (92.6%) | ns |
| Anti-IL17 | ||||
| Secukinumab | 13 (11.0%) | 2 (20.0%) | 11 (33.3%) (84.6%) | ns |
| Ixekizumab | 25 (21.2%) | 1 (10.0%) | 24 (22.2%) (96.0%) | ns |
| Brodalumab | 6 (5.1%) | 1 (10.0%) | 5 (4.6%) (83.3%) | ns |
| Anti-IL23 | ||||
| Risankizumab | 1 (0.9%) | 1 (10.0%) | 0 | ns |
| Guselkumab | 11 (9.3%) | 0 | 11 (10.2%) (100%) | ns |
| Tildrakizumab | 4 (3.4%) | 0 | 4 (3.7%) (100%) | ns |
ns stands for non-significant.